Sandoz Head Francis To Leave Amid Move Towards Autonomy
Executive Summary
Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
You may also be interested in...
Sandoz Sets Forth On Quest To Raise Its Margins
Sandoz is set to undergo a transformation in terms of operational efficiency, geographic footprint and portfolio offering in a bid to lift its operating margin from the mid-teens range towards 20%.
Autonomous Sandoz Set To Be Tighter And Leaner
With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.
Transformed Sandoz Is Important Part Of Novartis
A Sandoz generics division that is focusing more on biosimilars and hard-to-make small molecules remains “an important part of Novartis”, the Swiss group’s chief executive officer, Vas Narasimhan, told investors during a J.P. Morgan Healthcare Conference.